NeoGenomics (NASDAQ:NEO – Get Free Report) released its quarterly earnings data on Tuesday. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04, Briefing.com reports. The company had revenue of $167.80 million for the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted ($0.06) EPS. NeoGenomics updated its FY 2024 guidance to 0.080-0.100 EPS.
NeoGenomics Stock Up 2.3 %
NEO traded up $0.36 during trading on Thursday, hitting $15.82. The company had a trading volume of 940,050 shares, compared to its average volume of 820,345. NeoGenomics has a 1-year low of $12.77 and a 1-year high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The company has a market cap of $2.03 billion, a PE ratio of -24.94 and a beta of 1.19. The business has a 50-day moving average of $14.71 and a 200-day moving average of $14.73.
Analyst Upgrades and Downgrades
NEO has been the topic of a number of recent research reports. Benchmark restated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday. Finally, Stephens reissued an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.89.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
- Five stocks we like better than NeoGenomics
- Most active stocks: Dollar volume vs share volume
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Breakout Alert: Qualcomm Just Hit The Rally Button
- What to Know About Investing in Penny Stocks
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
